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Abstract: Quantitative structure-activity relationship (QSAR) and docking studies have been 
performed on a large series of cinnamic acid analogues studied by various authors as Epidermal 
Growth Factor Receptor (EGFR) inhibitors. A multiple linear regression (MLR) analysis has 
shown that electronic properties of these compounds are the governing factors of their activity 
and docking study has shown that compounds can form hydrogen bonds with the receptor and 
have effective steric interactions involving dispersion forces. Using the MLR model, some new 
compounds were proposed that have higher potency than the existing ones. 
Keywords: Cinnamic acid analogues, epidermal growth factor receptor (EGFR) inhibitors, tyrosine kinase, quantitative struc-
ture-activity relationship study, docking study. 
INTRODUCTION 
Presently, it is felt that there is a serious need for new 
targets to develop anticancer drugs. It has been found that a 
protein tyrosine kinase (PTK), epidermal growth factor re-
ceptor (EGFR), has been associated with many human can-
cers, such as breast and liver cancers. This led many to con-
sider that EGFR can be an attractive target for the develop-
ment of anticancer drugs. Conservative cytotoxic drugs for 
cancer chemotherapy have been usually found to be associ-
ated with severe toxic side effects, while drugs intended to 
inhibit molecular targets are found to show high selectivity 
and low toxicity. Therefore, searching small molecules to 
inhibit EGFR activities shows great promise in developing 
new anticancer agents. 
A naturally occurring aromatic fatty acid of low toxicity, 
cinnamic acid, is quite well exposed to human and its amide 
derivatives with cyano and fluoro substituents have been 
found to be of particular value due to their inhibitory effect 
in mitochondrial pyruvate transport. They were reported to 
have many different biological activities such as anticancer 
and antioxidant effects [1-3]. The simple substituents on 
their N-phenyl ring affect the EGFR inhibitory activities. 
Nitroimidazole derivatives have attracted significant atten-
tion as they showed affinity to penetrate and accumulate in 
regions of tumors. They can experience bioreduction to yield 
*Address correspondence to this author at the Department of Applied  
Sciences, NITTTR, Shamla Hills, Bhopal-462002, Madhya Pradesh, India; 
Tel: + 91-4449534745; Fax: +91-755-2661996; E-mail: spgbits@gmail.com 
electrophilic substances which can damage protein and nu-
cleic acids. The toxicology and metabolism of nitroimida-
zoles, particularly metronidazole, have been characterized. 
As a novel class of bioreductively activated nitroimidazole 
compounds, a series of cinnamic acid metronidazole ester 
derivatives were synthesized and evaluated for their biologi-
cal activity to find that some of them had anticancer activity 
[4]. A combination of 4-anilinoquinazoline and cinnamic 
acid was found to have a novel mode of binding to the EGFR 
tyrosine kinase [5]. EGFR inhibitors are used to treat non-
small-cell lung cancer, pancreatic cancer, breast cancer, co-
lon cancer and some other cancers that are caused by epi-
dermal growth factor receptor up-regulation.
In designing new drugs, biological activity estimation 
forms the basis for compound selection and optimization. 
While several experimental methods are available for screen-
ing the biological activity of compounds, they are somehow 
too expensive and time consuming. Quantitative structure-
activity relationship (QSAR) analysis provides an effective 
and powerful tool for achieving the same goal with much 
lower cost. The aim of this work is to apply different statisti-
cal methods to explore the crucial structural properties of the 
compounds that are associated with their EGFR inhibitory 
activities. QSAR models were constructed for a combined 
data set of 54 compounds having EGFR inhibitory activity, 
which was retrieved from the literature [3-5]. The strength 
and the predictive performance of the proposed models were 
verified using both internal (cross-validation and Yscram-
bling) and external statistical validations. In order to explore 
the scope of further modification in the structures of the 
1875-628X/17 $58.00+.00 ©2017 Bentham Science Publishers
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compounds leading to further increase in the potency, we 
have performed docking studies on some predicted com-
pounds.   
MATERIALS AND METHODS 
We have taken three similar series of cinnamic acid 
analogues (1-3) that were synthesized and evaluated for their 
EGFR inhibitory activity by various workers [3-5]. A 
combination of these series is listed in Table 1 along with the 
EGFR inhibitory activities of the compounds. The chemical 
structures were drawn using ChemDoodle software [6]. 
Table 1 also lists the topological parameters of the 
compounds that were found to govern their potency. These 
topological parameters used have been calculated using 
Dragon software [7]. Among the thousands of parameters 
that were calculated, Table 1 lists only those parameters that 
were found to be important. These were frequency of C-O at 
topological distance 10, (F10[C-O]); spectral mean absolute 
deviation from Burden matrix weighted by ionization poten-
tial, (SpMADB(i)); Geary autocorrelation of lag 8 weighted 
by mass, (GATS8m); and Moran autocorrelation of lag 4 
weighted by Sanderson electronegativity, (MATS4e).
RESULTS & DISCUSSION  
Of the total dataset comprising of 54 compounds (Table
1), 40 compounds were selected for training set and 14 com-
pounds were used for the test set to evaluate the predictabil-
ity of the developed models. The test set compounds are in-
dicated in the table by a bold superscript ‘b’. The QSAR 
models were obtained using QSARINs software [8-10]. The 
generation of training and test sets is done using split option 
present in QASRINs software by choosing the molecules on 
random basis. For obtaining QSAR models, Genetic 
Algorithm-Multi Linear Regression (GA-MLR) was 
employed using default settings in QSARINS. For statistical 
validation, variety of statistical parameters were calculated. 
The best GA-MLR equation based on four descriptors along 
with statistical parameters were as follows. 
pIC50 = 0.2019(±0.0339) F10[C-O] + 
3.7300(±1.5732)SpMADB(i)  0.7758(±0.3664)GATS8m + 
0.8473(±0.5829)MATS4e  0.1609         (1) 
N = 39, R2tr = 0.842, R2adj. = 0.824, S= 0.182, F= 45.401, Kxx 
= 0.253, K = 0.089,  
RMSEtr = 0.170, MAEtr = 0.142, RSStr = 1,133, CCCtr = 0.914 
Q2LOO = 0.776, RMSEcv = 0.203, MAEcv = 0.168, PRESSCV = 
1.612, CCCCV = 0.878,  
Q2LMO = 0.766, R2Yscr =0.105, Q2Yscr = -0.195, R2Pred = 
0.411, RMSEext = 0.348,  
MAEext = 0.284, PRESSext = 1.571, CCCext = 0.594, R2m = 
0.327 
pIC50 = 0.1873(±0.0358) F10[C-O] + 
3.1318(±1.6759)SpMADB(i)  0.6918(±0.3994)GATS8m +
0.6745                                        (2)
N = 39, R2tr = 0.802, R2adj. = 0.785, S= 0.202, F= 47.204, Kxx 
= 0.201, K = 0.137,  
RMSEtr = 0.191, MAEtr = 0.158, RSStr = 1.423, CCCtr = 0.890 
Q2LOO = 0.721, RMSEcv = 0.227, MAEcv = 0.183, PRESSCV = 
2.003, CCCCV = 0.845,  
Q2LMO = 0.705, R2Yscr =0.081, Q2Yscr = -0.154, R2Pred = 
0.400, RMSEext = 0.351,  
MAEext = 0.296, PRESSext = 1.602, CCCext = 0.550, R2m = 
0.4110 
pIC50 = 0.1642(±0.0380) F10[C-O] + 
3.4820(±1.9064)SpMADB(i)  0.5804                                (3) 
N = 39, R2tr = 0.732, R2adj. = 0.717, S= 0.213, F= 49.116, Kxx 
= 0.104, K = 0.363,  
RMSEtr = 0.222, MAEtr = 0.173, RSStr = 1.926, CCCtr = 0.845 
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Q2LOO = 0.671, RMSEcv = 0.246, MAEcv = 0.191, PRESSCV = 
2.367, CCCCV = 0.806,  
Q2LMO = 0.655, R2Yscr = 0.053, Q2Yscr = -0.118, R2Pred = 
0.337, RMSEext = 0.368,  
MAEext = 0.327, PRESSext = 1.764, CCCext = 0.507, R2m = 
0.328 
pIC50 = 0.1714(±0.0438) F10[C-O] + 4.8101      (4) 
N = 39, R2tr = 0.630, R2adj. = 0.620, S= 0.268, F= 62.887, Kxx 
= 0.000, K = 0.794,  
RMSEtr = 0.261, MAEtr = 0.208, RSStr = 2.661, CCCtr =
0.7727 
Q2LOO = 0.590, RMSEcv = 0.274, MAEcv = 0.220, PRESSCV = 
2.9479, CCCCV = 0.742,  
Q2LMO = 0.584, R2Yscr =0.0272, Q2Yscr = -0.0847, R2Pred = 
0.357, RMSEext = 0.364,  
MAEext = 0.317, PRESSext = 1.7214, CCCext = 0.4934, R2m = 
0.436 
Among the statistical parameters, N is the number of data 
points (compounds), R2tr is the correlation coefficient of 
training set compounds, Q2LOO is the square of the cross-
validated correlation coefficient obtained from leave-one-out 
(LOO), S is the standard deviation, and F is Fischer ratio 
between the variances of calculated and observed activities. 
The remaining symbols have their usual meaning given by 
various researchers [11-17]. 
Of the above four models, the very first model (eq. 1) is 
found to be statistically most significant. The validation of 
models using different statistical parameters indicates that 
the models have not occurred by chance. In models 1-4, the 
descriptor F10[C-O], which is a 2D atom pair descriptor, has 
positive coefficient means that the frequency of C-O at 
topological distance 10 is conducive to the inhibitory 
activity. Similarly, the positive coefficients of SpMADB(i)
and MATS4e suggest that ionization potential and 
electronegativity of the molecules have positive effect on the 
potency of the compounds. The negative coefficient of 
GATS8m, however, indicates that massive molecule will 
have adverse effect. Thus, this model suggested that the po-
tency of the compounds are governed by their electronic 
properties. All the parameters used in the models appear to 
be significant, because if they are removed one by one the 
significance of the model decreases (eqs. 1-4). 
The model expressed by eq. 1 was found to have good 
predictive ability when the activities of both the training and 
test set compounds were compared with their corresponding 
observed activities. A graph drawn between calculated and 
observed activities also verifies this fact (Fig. 1). Using this 
model we predicted some new compounds of high EGFR 
inhibition potency as shown in Table 2. Each predicted com-
pound has higher potency than any compound in the existing 
series. Their potency is higher even than Erlotinib (com-
pound 23, Table 1, also given in Table 2 for direct compari-
son). All these predicted compounds follow the Lipinski rule 
of 5, according to which an orally active drug molecule 
should not have its hydrogen-bond donors (NH + OH) > 5, 
hydrogen-bond acceptors (N + O) > 10, molecular weight > 
500, and logP value > 5 (Table 3). 
DOCKING STUDY 
A docking study was performed on the predicted com-
pounds using Lead IT FlexX software to see the binding of 
these compounds with the EGFR. The ability of a molecule 
to interact with an enzyme decides its potency. For the study 
of docking, the crystal structure of the related enzyme is re-
quired which can now be retrieved from RCSB protein data 
bank. We selected the Erlotinib-enzyme complex with PDB 
entry code 1M17 (http://www.pdb.org). Erlotinib is the FDA 
approved EGFR inhibitor. Its structure is given in Table 2,
but for the sake of convenience it is shown as 4 given below. 
The docking results are shown in Table 4. This table shows 
that all the  
4, Erlotinib 
predicted compounds, except 12, have hydrogen bonds equal 
to or greater than Erlotinib (4) and all of them have compa-
rable docking scores. It can be seen that among all the pre-
dicted compounds, compound 7 has the highest activity 
(pIC50 = 7.34), and much higher than Erlotinib (pIC50 = 
6.47). We made a comparative study of the interactions of 
these two compounds with the enzyme. The interactions of 
Erlitinib are shown in Figure 2 and that of compound 7 in 
Figure 3. Figure 2 shows that in addition to forming 3 hy-
drogen bonds as described in Table 4, Erlotinib also interacts 
with the enzyme through its various rings and side chains. Its 
aryl ring with acetylenic moiety is engulfed in a deep pocket 
of the enzyme formed by Pro770, Leu 694, and Leu768 resi-
dues and undergoes steric interaction. Similarly, heterocyclic 
ring of quinazoline interacts with a shallow trough of the 
enzyme constituted of only Met769, and its benzene ring 
faces a convex surface of the enzyme. An ester chain at the 
5-position of the quinazoline ring tries to penetrate the shal-
low gulf formed by Gly 772 and Cys773 residues. In Figure
3, that shows the binding of predicted compound 7, it is ob-
served that there are deep penetrations of crucial moieties of 
the compound in three deep pockets of the enzyme. A pocket 
formed by Asp831 and Phe699 engulfs a large portion of the 
pendent substituent at position 1 of the central ring, a pocket 
formed by Leu768, Leu694, Met769, and Leu820 engulfs the 
fluoro-substituted alkyl moiety of side chain, and a pocket 
formed by Thr766, Lys721, Val702, and Ala719 interacts 
with the alkyl moiety of the other side chain. The central ring 
also faces a convex surface of the residue Thr830. All these 
interactions are steric interactions, involving dispersion 
forces. Additionally, the molecule also forms three hydrogen 
bonds with the receptor as described in Table 4.
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Table 1. List of Compounds Acting as EGFR Inhibitors and Their Potency and Related Structural Variables. 
pIC50a
No Structure F10[C-O] SpMADB(i) GATS8m MATS4e 
Obsd. Cald. eq. 1 LOO
d
1b 0 1.61 1.04 -0.02 4.64 5.03 - 
2 0 1.58 0.92 -0.10 4.91 4.95 4.95 
3 0 1.56 1.01 0.03 4.71 4.91 4.92 
4 0 1.58 1.28 -0.01 4.90 4.74 4.71 
5 0 1.54 1.00 0.00 4.84 4.82 4.82 
6 1 1.58 0.90 -0.12 5.29 5.13 5.12 
7b 2 1.58 0.98 -0.09 5.04 5.30 - 
8 1 1.55 1.04 -0.12 5.03 4.93 4.93 
9 2 1.55 1.08 -0.09 4.99 5.13 5.13 
10 0 1.58 0.89 -0.14 5.13 4.93 4.91 
11 0 1.58 1.06 -0.09 5.00 4.84 4.83 
12 0 1.56 0.95 0.07 4.93 4.99 4.99 
13 0 1.55 1.11 0.33 4.88 5.03 5.10 
14 0 1.54 1.17 0.19 4.89 4.82 4.81 
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Table 1. contd… 
pIC50a
No Structure F10[C-O] SpMADB(i) GATS8m MATS4e 
Obsd. Cald. eq. 1 LOO
d
15 0 1.58 0.83 -0.13 5.01 4.98 4.98 
16 0 1.57 1.04 0.07 4.84 4.93 4.94 
17 0 1.58 1.04 -0.09 4.86 4.85 4.85 
18 0 1.55 0.92 -0.01 4.79 4.88 4.89 
19 0 1.52 1.07 0.29 4.86 4.93 4.95 
20 0 1.58 0.85 -0.11 4.80 4.98 5.00 
21 1 1.42 1.01 -0.02 4.41 4.55 4.62 
22 0 1.42 1.37 0.17 4.53 4.23 4.04 
23 8 1.53 1.14 0.04 6.47 6.30 6.20 
24b 2 1.52 1.02 -0.12 5.39 5.02 - 
25b 2 1.51 0.85 -0.11 5.44 5.12 - 
26 2 1.51 0.73 -0.10 5.49 5.24 5.17 
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Table 1. contd… 
pIC50a
No Structure F10[C-O] SpMADB(i) GATS8m MATS4e 
Obsd. Cald. eq. 1 LOO
d
27 2 1.55 1.19 -0.07 5.11 5.03 5.03 
28b 2 1.51 1.04 -0.03 5.09 5.06 - 
29 3 1.52 1.01 -0.09 4.96 5.27 5.29 
30 2 1.50 1.00 0.00 5.17 5.06 5.05 
31b 6 1.58 1.05 -0.03 6.21 6.09 - 
32 5 1.55 0.98 -0.08 5.90 5.81 5.80 
33 2 1.52 1.30 -0.17 4.57 4.77 4.80 
34 2 1.51 1.33 -0.15 4.68 4.72 4.73 
35 2 1.51 1.29 -0.13 4.61 4.78 4.80 
36b 2 1.54 1.20 -0.17 4.60 4.93 - 
Pe
rso
na
l U
se
 O
nly
 
No
t fo
r D
ist
rib
uti
on
 
 
QSAR and Molecular Docking Studies on a Series of Cinnamic Acid Letters in Drug Design & Discovery, 2017, Vol. 14, No. 1    89
Table 1. contd… 
pIC50a
No Structure F10[C-O] SpMADB(i) GATS8m MATS4e 
Obsd. Cald. eq. 1 LOO
d
37c 4 1.52 1.43 -0.13 - - - 
38c 4 1.54 1.06 -0.16 - - - 
39b 2 1.52 1.12 -0.10 4.91 4.96 - 
40b 2 1.52 1.07 -0.08 4.86 5.03 - 
41 2 1.58 1.31 -0.04 5.41 5.07 5.04 
42 2 1.58 1.09 -0.04 5.24 5.25 5.25 
43b 2 1.57 1.28 -0.06 5.92 5.05 - 
44 2 1.57 1.02 -0.07 5.37 5.24 5.24 
45b 4 1.58 1.32 -0.06 5.14 5.45 - 
46 4 1.58 1.36 -0.09 5.11 5.39 5.43 
47b 4 1.58 1.34 -0.03 5.22 5.46 - 
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Table 1. contd… 
pIC50a
No Structure F10[C-O] SpMADB(i) GATS8m MATS4e 
Obsd. Cald. eq. 1 LOO
d
48 4 1.59 1.37 -0.12 5.29 5.42 5.45 
49 6 1.59 1.37 -0.11 5.99 5.83 5.80 
50 2 1.60 1.23 0.01 5.44 5.25 5.23 
51 2 1.57 0.70 -0.03 5.46 5.53 5.54 
52 4 1.58 1.18 -0.02 5.18 5.59 5.62 
53b 2 1.62 1.24 0.01 5.55 5.31 - 
54 6 1.59 1.22 -0.10 6.03 5.96 5.94 
aAll observed data were taken from refs. [3-5], IC50 values were in M concentration. b Test set compounds. c Outliers. dLeave-one-out (Jackknife procedure) 
Table 2. Some Proposed Compounds Belonging to the Series of Table 1 and their Predicted Activity. 
No. Structure F10[C-O] SpMAD_B(i) GATS8m MATS4e Pred Act. eq.1 
1 11 1.449 0.954 0.08 6.79 
2 11 1.449 0.952 0.125 6.83 
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Table 2. contd… 
No. Structure F10[C-O] SpMAD_B(i) GATS8m MATS4e Pred Act. eq.1 
3 11 1.462 0.899 -0.113 6.72 
4 11 1.462 0.867 -0.144 6.72 
5 13 1.462 0.823 -0.085 7.21 
6 13 1.462 0.792 -0.12 7.20 
7 13 1.449 0.872 0.173 7.34 
8 13 1.449 0.874 0.122 7.29 
9 11 1.453 0.893 0.167 6.93 
10 11 1.454 0.891 0.187 6.95 
Pe
rso
na
l U
se
 O
nly
 
No
t fo
r D
ist
rib
uti
on
 
 
92    Letters in Drug Design & Discovery, 2017, Vol. 14, No. 1 Shaik et al.
Table 2. contd… 
No. Structure F10[C-O] SpMAD_B(i) GATS8m MATS4e Pred Act. eq.1 
11 12 1.456 0.932 0.2 7.14 
12 13 1.451 0.929 0.13 7.27 
13
Erlotinib
8 1.53 1.14 0.04 6.47a
aAs reported in ref [3].    
Table 3. Data Related to Lipinski Rules and Activity Values of Predicted Compounds.
Compd  HD HA MW (AlogP)a pIC50
1 2 8 499.457 3.112 6.79 
2 3 8 500.488 2.729 6.83 
3 3 8 500.488 3.541 6.72 
4 2 8 501.473 4.188 6.72 
5 3 8 500.488 3.541 7.21 
6 2 8 501.473 4.188 7.20 
7 3 8 500.488 2.729 7.34 
8 2 8 501.473 3.376 7.29 
9 2 8 501.473 3.376 6.93 
10 3 8 500.488 2.729 6.95 
11 1 7 493.472 4.228 7.14 
12 0 7 490.493 5.302 7.27 
aAtom based calculated logP. 
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Table 4. Docking Results of Predicated Molecules with Reference to FDA Approved Molecule. 
Compd. No. No. of Hydrogen Bonds H-bonds H-bonds Length (Å) Score 
1 2 
O(28)-Asp831 
N(30)-Lys721 
-4.70 
-8.30 
-8.0881 
2 3 
O(28)-Asp831 
N(30)-Lys721 
O(25)-Lys721 
-2.68 
-8.30 
-3.46 
-13.4961 
3 3 
N(30)-Lys721 
O(20)-Lys721 
O(29)-Asp831 
-8.30 
-2.76 
-4.70 
-12.9483 
4 3 
N(30)-Lys721 
O(20)-Lys721 
O(29)-Asp831 
-8.30 
-4.21 
-4.70 
-9.4459 
5 3 
O(21)-Met769 
H(42)-Met769 
O(32)-Cys773 
-4.18 
-4.70 
-4.70 
-10.8692 
6 3 
O(33)-Asp831 
N(34)-Lys721 
O(17)-Lys721 
-4.70 
-8.30 
-4.70 
-11.5870 
7 3 
O(30)-Asp831 
H(42)-Asp831 
N(31)-Lys721 
-4.12 
-2.81 
-8.30 
-14.2482 
8 3 
O(17)-Lys721 
N(31)-Lys721 
O(30)-Asp831 
-4.70 
-8.30 
-4.70 
-12.9263 
9 3 
O(17)-Cys773 
O(33)-Met769 
H(56)-Thr766 
-3.07 
-4.70 
-4.70 
-8.3986 
10 3 
O(21)-Cys773 
H(42)-Met769 
H(57)-Thr830 
-3.61 
-4.70 
-4.03 
-8.2246 
11 2 
H(43)-Asp776 
O(17)-Cys773 
-4.41 
-4.52 
-6.5071 
12 1 O(34)-Lys721 -4.70 -7.2109 
Erlotinib 3 
   O(8)-Cys773 
 O(11)-Cys773 
N(1)-Met769 
-2.58 
-3.00 
-16.247 
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Fig. (1). A graph between the calculated and observed activities of compounds of Table 1.
Fig. (2). A docked structure of Erlotinib in EGFR (PDB entry code 
1M17). 
CONCLUSION 
All the cinnamic acid analogues studied as EGFR inhibi-
tors are found to interact with the receptors involving elec-
tronic interactions. Their docking study shows that they also 
form hydrogen bonds and perform steric interactions with 
certain deep pockets available in the enzyme. Similar con-
clusions were also drawn regarding the binding of different 
categories of chemicals with EGFR, when QSAR and mo-
lecular modeling studies were performed on them by differ-
ent authors [18-20]. Electronic interactions and hydrogen 
bondings were found to be important in many other cases 
also such as in H+/K+-ATPase inhibition, recently studied by 
Agarwal et al. [21]. In the present case, the enzyme is also 
found to possess several deep pockets in which different por-
tions of inhibitors are engulfed, e.g., in Figure 2 a deep 
pocket of the enzyme formed by Pro770, Leu 694, and 
Leu768 residues engulfs Erlotinib’s aryl ring with acetylenic 
moiety. Similarly in Figure 3, which shows the interactions 
Fig. (3). A docked structure of predicted compound 7 (Table 3) in 
EGFR (PDB entry code 1M17). 
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of compound 7, one of the predicted compounds, a pocket 
formed by Asp831 and Phe699 engulfs a large portion of the 
pendent substituent at position 1 of the central ring and a 
pocket formed by Leu768, Leu694, Met769, and Leu820 
engulfs the fluoro-substituted alkyl moiety of side chain. 
These are some of the major steric interactions shown in 
both the figures. Besides, there are some minor steric inter-
actions which contribute to the activity of the compounds. It 
has been shown that compound 7 has better interactions with 
the enzyme than Erlotinib, and that is why its activity is 
higher than that of Erlotinib. It may be suggested that bulky 
compounds with better flexibility may possess good EGFR 
inhibition potency. 
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